SGLT2 inhibition: an effective therapeutic approach in the treatment of diabetes mellitus?

被引：0

作者：

Rudofsky, G. ^{[1
]}

Ruessmann, H. -J.

Siegmund, T. ^{[2
]}

机构：

[1] Univ Klinikum Heidelberg, Abt Innere Med & Klin Chem 1, D-69120 Heidelberg, Germany

[2] Stadt Klinikum Munchen GmbH, Klinikum Bogenhausen, Klin Endokrinol Diabetol & Angiol, Munich, Germany

来源：

DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2013年 / 138卷 / 22期

关键词：

blood pressure; type; 2; diabetes; weight reduction; glucosuria; drug therapy; Sodium Glucose Linked Transporter (SGLT); INADEQUATE GLYCEMIC CONTROL; DOUBLE-BLIND; DAPAGLIFLOZIN TREATMENT; ADD-ON; TYPE-2; KIDNEY; METFORMIN; CANAGLIFLOZIN; TRANSPORT; WEIGHT;

D O I：

10.1055/s-0032-1333023

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Since end of 2012 a new therapeutical approach for the treatment of type 2 diabetes is available in Germany. It relies on the modulation of glucose re-absorption in the kidney by inhibition of so called Sodium Glucose Linked Transporters (SGLT) thereby leading to therapeutical glucosuria. Putting the kidney in the centre of therapeutical approach of glucose regulation is unfamiliar for physicians. Therefore, it is helpful to elucidate the underlying renal mechanisms and to present the advantages and disadvantages of this new therapeutic class. © Georg Thieme Verlag KG, Stuttgart New York.

引用

页码：1172 / 1177

页数：6

共 50 条

[21] Investigational Agents Targeting SGLT1 and SGLT2 in the Treatment of Type 2 Diabetes Mellitus
Cui, Haigang
Luo, Xin
Chen, Mingwei
Lu, Jun
Liu, Johnson J. J.
CURRENT DRUG TARGETS, 2023, 24 (08) : 648 - 661
[22] SGLT2 inhibition with dapagliflozin A novel approach for the management of type 2 diabetes
Kilov, Gary
Leow, Stephen
Thomas, Merlin
AUSTRALIAN FAMILY PHYSICIAN, 2013, 42 (10) : 706 - 710
[23] Diabetes mellitus and SGLT(2) -Inhibition
Boehm, M.
KARDIOLOGE, 2018, 12 (04): : 232 - 232
[24] DIABETES MELLITUS Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS
Vallon, Volker
Thomson, Scott C.
NATURE REVIEWS NEPHROLOGY, 2017, 13 (09) : 517 - 518
[25] Safety of SGLT2 Inhibitors in Patients with Diabetes Mellitus
Singh, Mahakpreet
Sharma, Ruchika
Kumar, Anoop
CURRENT DRUG SAFETY, 2019, 14 (02) : 87 - 93
[26] The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Hadi Fattah
Volker Vallon
Drugs, 2018, 78 : 717 - 726
[27] The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
Fattah, Hadi
Vallon, Volker
DRUGS, 2018, 78 (07) : 717 - 726
[28] POTENTIAL PLACE OF SGLT2 INHIBITORS IN TREATMENT PARADIGMS FOR TYPE 2 DIABETES MELLITUS
Handelsman, Yehuda
ENDOCRINE PRACTICE, 2015, 21 (09) : 1054 - 1065
[29] Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment
Rizzo, Maria Rosaria
Di Meo, Irene
Polito, Rita
Auriemma, Maria Chiara
Gambardella, Antonio
di Mauro, Gabriella
Capuano, Annalisa
Paolisso, Giuseppe
PHARMACOLOGICAL RESEARCH, 2022, 176
[30] Empagliflozin, an SGLT2 Inhibitor for the Treatment of Type 2 Diabetes Mellitus: A Review of the Evidence
White, John R., Jr.
ANNALS OF PHARMACOTHERAPY, 2015, 49 (05) : 582 - 598

← 1 2 3 4 5 →